Roivant Sciences ROIV

HealthcareMarket cap $26B1 connection

Roivant is a drug development holding company that acquires and develops drug candidates using a 'vant' model - creating subsidiaries (Dermavant, Kiniksa, etc.) around each asset. Its Immunovant subsidiary's batoclimab and its commercial immunology drug Vtama (tapinarof) represent its most valuable near-term assets.

Open Roivant Sciences's Company Hub Simulate a merger Supply chain See it on the map

Stakes owned 1

Companies Roivant Sciences owns or has invested in

ImmunovantHealthcare · $7BRoivant Sciences is majority owner of Immunovant

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Roivant Sciences's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=ROIV" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Roivant Sciences on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.